H.C. Wainwright raised the firm’s price target on Verve Therapeutics (VERV) to $25 from $15 and keeps a Buy rating on the shares after the company reported Phase 1 data for its one-time gene editing treatment, VERVE-102, in patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease. Following the data, the firm is increasing its view on the probability of success for VERVE-102 to 55% from 40%, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Buy Rating for Verve Therapeutics: Promising Safety and Efficacy of VERVE-102 in Phase 1b Heart-2 Study
- Verve announces initial data from Heart-2 Phase 1b trial of VERVE-102
- Verve Therapeutics receives FDA Fast Track designation for VERVE-102
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech